Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches

Published on: 
Pharmaceutical Executive, Pharmaceutical Executive: September 2023, Volume 44, Issue 9

Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.

Follow the links below to read about each product:

Camzyos (Bristol Myers Squibb)

Enhertu (Daiichi Sankyo, AstraZeneca)


Rebyota (Ferring Pharmaceuticals)

Sunlenca (Gilead Sciences)

Tzield (Provention Bio, a Sanofi company)

Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.